Alkermes (ALKS) Change in Accured Expenses (2010 - 2026)

Alkermes' (ALKS) quarterly Change in Accured Expenses came in at -$119.5 million in Q1 2026, down 7007.2% year-on-year from $1.7 million in Q1 2025, and down 429.32% on a QoQ basis from -$22.6 million in Q4 2025.

Alkermes (ALKS) Change in Accured Expenses (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has 17 years of Change in Accured Expenses data on file, last reported at -$119.5 million in Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 7007.2% year-over-year to -$119.5 million in Q1 2026; TTM through Mar 2026 was -$112.5 million, a 348.91% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, down 37.21% from the prior year.
  • Change in Accured Expenses for Q1 2026 stood at -$119.5 million, down from -$22.6 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for ALKS reached as high as $91.4 million in Q4 2024 and fell as low as -$119.5 million in Q1 2026.
  • Historically, Change in Accured Expenses has averaged -$4.1 million across 5 years, with a median of $1.8 million in 2022.
  • Across the five-year window, Change in Accured Expenses tumbled 39101.72% in 2022 and surged 4356.75% in 2024, its largest moves.
  • Year by year, Change in Accured Expenses stood at $6.3 million in 2022, then tumbled by 67.65% to $2.1 million in 2023, then jumped by 4356.75% to $91.4 million in 2024, then plunged by 124.69% to -$22.6 million in 2025, then plunged by 429.32% to -$119.5 million in 2026.
  • Per Business Quant data, the three most recent Change in Accured Expenses figures were -$119.5 million in Q1 2026, -$22.6 million in Q4 2025, and -$28.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -144.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -234.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -12.70 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -14.30 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 Alkermes 9.72 Bn 9.21 Bn 331.33 Mn -119.47 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -119.47 Mn
Mar 31, 2026 -119.47 Mn
Dec 31, 2025 -22.57 Mn
Dec 31, 2025 -22.57 Mn
Sep 30, 2025 -28.25 Mn
Sep 30, 2025 -28.25 Mn
Jun 30, 2025 57.79 Mn
Jun 30, 2025 57.79 Mn
Mar 31, 2025 -1.68 Mn
Mar 31, 2025 -1.68 Mn
Dec 31, 2024 91.41 Mn
Dec 31, 2024 91.41 Mn
Sep 30, 2024 -83.99 Mn
Sep 30, 2024 -83.99 Mn
Jun 30, 2024 39.46 Mn
Jun 30, 2024 39.46 Mn
Mar 31, 2024 -38.45 Mn
Mar 31, 2024 -38.45 Mn
Dec 31, 2023 2.05 Mn
Dec 31, 2023 2.05 Mn